Form 4: Abeona Therapeutics Director Sells Shares Under Pre-Arranged Trading Plan

Donald A. Wuchterl, a director at Abeona Therapeutics Inc., sold 5,176 shares of common stock for a weighted average price of $5.8244 per share, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Donald A. Wuchterl, a Director of Abeona Therapeutics Inc. (ABEO), reported a transaction involving the company's common stock.
• On July 8, 2025, Mr. Wuchterl sold 5,176 shares of common stock.
• The shares were sold at a weighted average price of $5.8244 per share, with individual transaction prices ranging from $5.74 to $5.87.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, which Mr. Wuchterl adopted on November 23, 2024.
• Following this transaction, Mr. Wuchterl beneficially owns 145,436 shares of Abeona Therapeutics Inc. common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While a director's sale of shares can be perceived negatively, the fact that it was conducted under a pre-established Rule 10b5-1 plan mitigates the negative signal, indicating a planned liquidity event rather than a reaction to adverse company news.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to recent events, which can reduce concerns about insider sentiment.

Negatives

• A director's sale of shares, even if pre-planned, reduces insider ownership and can sometimes be perceived negatively by the market as it might suggest a lack of conviction in future share price appreciation.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports a past transaction.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. It is a routine disclosure of a director's share activity.

Related Party Transactions

• Donald A. Wuchterl, a director of Abeona Therapeutics Inc., sold 5,176 shares of common stock, which is considered a related party transaction due to his insider status.

Stakeholder Impact

• Shareholders may interpret the director's sale differently; some might view it as a negative signal, while others may see it as a routine, pre-planned transaction with no bearing on the company's fundamentals.

Key Dates

Keywords

Abeona Therapeutics, ABEO, Donald A. Wuchterl, Director, Insider Trading, Form 4, SEC Filing, Share Sale, Rule 10b5-1 Plan, Common Stock